Skip to Content

Moderna Inc MRNA

Morningstar Rating
$87.59 +0.60 (0.69%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

MRNA is trading at a 61% discount.
Price
$87.59
Fair Value
$145.00
Uncertainty
Very High
1-Star Price
$232.25
5-Star Price
$257.10
Economic Moat
Wbs
Capital Allocation
Fxwmgkxl

Bulls Say, Bears Say

Bulls

The stellar efficacy and safety profile of Moderna's COVID-19 vaccine offered rapid validation of the firm's mRNA technology.

Bears

Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRNA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$86.99
Day Range
$85.5388.57
52-Week Range
$62.55163.24
Bid/Ask
$92.35 / $92.50
Market Cap
$33.40 Bil
Volume/Avg
78,388 / 5.0 Mil

Key Statistics

Price/Earnings (Normalized)
31.99
Price/Sales
3.67
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
4.66%

Company Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
3,900

Competitors

Valuation

Metric
MRNA
PFE
BNTX
Price/Earnings (Normalized)
31.999.457.31
Price/Book Value
2.431.581.03
Price/Sales
3.672.653.13
Price/Cash Flow
7.9547.43
Price/Earnings
MRNA
PFE
BNTX

Financial Strength

Metric
MRNA
PFE
BNTX
Quick Ratio
2.221.909.99
Current Ratio
2.462.3810.37
Interest Coverage
−64.766.05877.79
Quick Ratio
MRNA
PFE
BNTX

Profitability

Metric
MRNA
PFE
BNTX
Return on Assets (Normalized)
−13.62%8.04%12.85%
Return on Equity (Normalized)
−18.51%16.96%14.68%
Return on Invested Capital (Normalized)
−18.82%11.79%13.50%
Return on Assets
MRNA
PFE
BNTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHqqc$537.7 Bil
VRTX
Vertex Pharmaceuticals IncYvmtd$108.4 Bil
REGN
Regeneron Pharmaceuticals IncJncplt$104.6 Bil
ARGX
argenx SE ADRFgcm$23.7 Bil
BNTX
BioNTech SE ADRMhtpq$22.0 Bil
ALNY
Alnylam Pharmaceuticals IncFmshrw$19.5 Bil
BMRN
Biomarin Pharmaceutical IncJrnlkpx$16.7 Bil
RPRX
Royalty Pharma PLC Class AClyrr$14.0 Bil
INCY
Incyte CorpGyvvxt$13.5 Bil

Sponsor Center